For the estimated 2.9 million people living with multiple sclerosis worldwide, the progressive erosion of walking ability represents one of the most debilitating consequences of the disease — and one of the hardest to address outside clinical settings. A new trial protocol published in BMJ Open signals a rigorous attempt to test whether that gap can be closed with wearable robotic technology used daily in participants' own homes.
The trial is a multicentre, single-blinded, randomised crossover design enrolling 28 adults with confirmed MS and moderate-to-severe disability (EDSS scores 5.0–7.0, a range spanning significant walking limitation through near-complete dependence on mobility aids). Participants cycle through two eight-week phases — daily home-based lower-limb exoskeleton use versus a control condition of structured physical activity advice — with an eight-week washout interval separating them. The primary endpoint is change in the Functional Assessment of Multiple Sclerosis physical composite score, a validated patient-reported quality-of-life measure. Secondary outcomes span an ambitious functional battery: 2-Minute Walk Test, 10-Meter Walk, Timed Up-and-Go, Four Square Step Test, Sit-to-Stand, fatigue scales, and additional patient-reported measures.
This protocol is noteworthy precisely because it moves exoskeleton research out of rehabilitation gyms and into ecologically valid home environments — a translation that most prior work has not made. Existing evidence for lower-limb exoskeletons in MS is largely confined to supervised, clinic-based sessions with small samples, leaving open questions about adherence, safety, and sustained benefit in unsupervised settings. The crossover design is efficient given the small MS subpopulation targeted, though 28 participants limits statistical power and generalizability. Critically, this is a protocol paper, not results — the findings that will actually inform clinical practice remain pending. The control arm of physical activity advice, rather than a sham device, also means participant blinding is incomplete. If results demonstrate meaningful QoL and functional gains, this could accelerate reimbursement pathways for wearable exoskeletons in MS rehabilitation — an incremental but potentially consequential step forward.